Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Garadacimab - CSL Behring

Next Previous
Drug Profile

Garadacimab - CSL Behring

Alternative Names: ANDEMBRY; Andembry; Anti-FXIIa mAb - CSL Behring; Anti-FXIIa monoclonal antibody - CSL Behring; CSL 312; Factor XIIa antagonist monoclonal antibody - CSL Behring

Latest Information Update: 25 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CSL Behring
  • Class Antibodies; Antifibrotics; Antithrombotics; Antivirals; Monoclonal antibodies; Skin disorder therapies; Vascular disorder therapies
  • Mechanism of Action Factor XIIa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Angioedema
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hereditary angioedema
  • Discontinued COVID 2019 infections; Idiopathic pulmonary fibrosis; Interstitial lung diseases

Most Recent Events

  • 18 Apr 2025 Launched for Hereditary angioedema (Prevention) in Japan (SC) - First global launch
  • 26 Feb 2025 Registered for Hereditary angioedema (Prevention, In children, In adolescents, In adults, In the elderly) in Switzerland (SC)
  • 20 Feb 2025 Registered for Hereditary angioedema (Prevention) in Japan (SC)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top